US 12,005,098 B2
Enzyme-rich malt extract (ERME) formulations
John Hunter, Ledbury (GB); and Rosemary Waring, Ledbury (GB)
Assigned to PEPSIS LIMITED, London (GB)
Appl. No. 16/461,977
Filed by PEPSIS LIMITED, Ledbury (GB)
PCT Filed Nov. 23, 2017, PCT No. PCT/GB2017/053516
§ 371(c)(1), (2) Date May 17, 2019,
PCT Pub. No. WO2018/096334, PCT Pub. Date May 31, 2018.
Claims priority of application No. 1619789 (GB), filed on Nov. 23, 2016.
Prior Publication US 2019/0307859 A1, Oct. 10, 2019
Int. Cl. C12Q 1/40 (2006.01); A23K 10/30 (2016.01); A23K 10/38 (2016.01); A23K 20/158 (2016.01); A23K 20/189 (2016.01); A23K 20/20 (2016.01); A23K 20/24 (2016.01); A23K 50/20 (2016.01); A61K 9/14 (2006.01); A61K 31/122 (2006.01); A61K 31/19 (2006.01); A61K 31/198 (2006.01); A61K 31/20 (2006.01); A61K 31/351 (2006.01); A61K 31/352 (2006.01); A61K 31/366 (2006.01); A61K 31/7008 (2006.01); A61K 33/06 (2006.01); A61K 33/24 (2019.01); A61K 36/185 (2006.01); A61K 36/45 (2006.01); A61K 36/889 (2006.01); A61K 38/47 (2006.01); A61K 45/06 (2006.01); C12Q 1/34 (2006.01)
CPC A61K 38/47 (2013.01) [A23K 10/30 (2016.05); A23K 10/38 (2016.05); A23K 20/158 (2016.05); A23K 20/189 (2016.05); A23K 20/24 (2016.05); A23K 20/30 (2016.05); A23K 50/20 (2016.05); A61K 9/14 (2013.01); A61K 31/122 (2013.01); A61K 31/19 (2013.01); A61K 31/198 (2013.01); A61K 31/20 (2013.01); A61K 31/351 (2013.01); A61K 31/352 (2013.01); A61K 31/366 (2013.01); A61K 31/7008 (2013.01); A61K 33/06 (2013.01); A61K 33/24 (2013.01); A61K 36/185 (2013.01); A61K 36/45 (2013.01); A61K 36/889 (2013.01); A61K 45/06 (2013.01); C12Q 1/34 (2013.01); C12Q 1/40 (2013.01); C12Y 302/01001 (2013.01); C12Y 302/01002 (2013.01); C12Y 302/0108 (2013.01); A23V 2250/00 (2013.01); A23V 2250/1578 (2013.01); A23V 2250/1586 (2013.01); A23V 2250/1612 (2013.01); A23V 2250/1878 (2013.01); A23V 2250/21 (2013.01); Y02P 60/87 (2015.11)] 16 Claims
 
1. A formulation comprising:
enzyme rich malt extract including a plurality of enzymatically active enzymes including at least fructanase and amylase; and
at least one biologically acceptable marker,
wherein the at least one biologically acceptable marker is calcium,
wherein the biologically acceptable marker has a concentration of 0.1-0.5% w/w formulation,
wherein the enzyme rich malt extract is derived from barley seeds,
wherein the amylase comprises alpha amylase and beta amylase, and
wherein the formulation is processed and configured to be stored at a temperature equal to or less than 75 degrees Centigrade.